Metastat and Allurion Technologies Compared in Critical Survey

Analysts believe Allurion Technologies has stronger consensus rating and higher potential upside than Metastat.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

A critical survey has compared medical companies Metastat (OTCMKTS:MTST) and Allurion Technologies (NYSE:ALUR), analyzing factors like profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. The analysis found that Allurion Technologies has a stronger consensus rating from analysts and higher potential upside, suggesting it is more favorable than Metastat.

Why it matters

This comparison provides valuable insights for investors looking to evaluate and choose between these two medical companies as potential investment opportunities. It highlights key differences in their financial performance, market positioning, and analyst sentiment.

The details

The survey found that Allurion Technologies has a consensus target price of $9.25, suggesting a potential upside of 438.73%, while analysts believe Metastat has lower revenue but higher earnings per share. Allurion Technologies also has a lower beta, indicating less volatility compared to the S&P 500. Overall, the analysis concludes that Allurion Technologies is more favorable than Metastat based on the factors examined.

  • The survey was published on February 23, 2026.

The players

Metastat

A precision medicine company focused on developing therapeutic and diagnostic solutions for cancer patients.

Allurion Technologies

A company that focuses on ending obesity with a weight loss platform featuring a swallowable and procedure-less intragastric balloon.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights the importance for investors to thoroughly evaluate multiple factors when assessing potential investments in the medical technology sector, as the relative strengths and weaknesses of companies can vary significantly.